A key aim for current genome-wide association studies (GWAS) is to interrogate the full 2 spectrum of genetic variation underlying human traits, including rare variants, across populations. 3
INTRODUCTION
For African Americans, who are underrepresented in the current version 1.1 of the HRC, 1 we constructed population-specific and HRC-augmented reference panels with 0 to 2,000 African 2 Americans. For Latino Americans, we used the same approach but restricted the study-specific 3 panel size to <1,500 due to the more limited available sample of sequenced Latino American 4 individuals. For Finns and Sardinians, which are present in the HRC, we constructed augmented 5 reference panels that comprised the 29,470 non-Finnish or 29,020 non-Sardinian individuals in the 6 HRC together with 0 to 2,000 Finns or Sardinians from the HRC. 7 8 For each population, each imputation strategy, and each of three commonly-used 11 genotyping arrays (Table 1) , we used sequence-based genotype calls at marker variants present on 12 the array as a scaffold for imputation using Minimac3, masking the remaining sequence-based 13 genotype calls 7 . We then compared the imputed genotype dosages to the true (masked) genotypes 14 to estimate (a) imputation 2 , the squared Pearson correlation between true genotype and imputed 15 dosage, and (b) imputation coverage, the proportion of variants with imputation 2 > 0.3 and minor 16 allele count (MAC) ≥ 5 (the MAC threshold used by the HRC panel 9 ) in the reference panel. 17 account for the interdependence between imputation 2 and the number of participants sequenced 3
, and for the possibility that the variant is not imputable (absent in the reference panel or not 4 imputed due to insufficient MAC, or filtered prior to association analysis due to imputation 2 5 falling below a given threshold). While common variant associations are likely to be captured by 6 LD proxy SNPs even when the causal variant is not directly genotyped or imputed, rare variant 7 associations are much less likely to be captured by proxy SNPs 27 . Here, we assume that power to 8 detect association for variants that are not imputable is zero. This assumption affects power 9 calculations almost exclusively for rare variants, since common variants are almost uniformly 10 imputable with large reference panels 7; 9 . 11
We assume that the participants who are sequenced are randomly subsampled from the 12 overall sample of + study participants, and that test statistics are calculated separately for the 13 sequenced and imputed subsamples and combined using the effective sample size weighted meta-14
, where = /( + 2 ). The 15 asymptotic distribution of − √ + 2 is normal with mean 0 and variance 1, where 2 is 16 the squared correlation between imputed dosages and true genotypes, and is an effect size 17 parameter which is equal to 0 under the null hypothesis of no association. The form of depends 18 on the association model (e.g. additive, dominant, multiplicative), relative risk or odds ratio, MAF, 19 and population prevalence and, for binary traits, the case-control ratio. Under an arbitrary 20 association model for binary traits, we can write 21 from experiments with real data described in the previous section. Specifically, we estimate power 6 to detect association when individuals are sequenced and are genotyped and imputed as 7
where
is the standard normal density function, 1− /2 is the -level 9 significance threshold, 2 is the imputation 2 value for the ℎ variant, = ( ≥ 10 5, 2 ≥ 0.3) is an indicator equal to 1 if the ℎ variant was imputable and 0 otherwise, and 11 is the reference panel MAC for the ℎ variant when the sequenced individuals from 12 the target population were included in the reference panel. 13
We define the first weight term = (̂)/̂(̂), where is the total number 14 of samples used in our analysis for the given population (e.g. =3,412 for African Americans), 15 ̂ is the sample MAF for the ℎ variant in the total sample, ̂( ) is the proportion of variants 16 with MAF = , and ( ) is the probability of observing sample MAF = in a sample of size 17
given the specified association model. For example, in a GWAS with sample size and case-18 control ratio , the sample MAC (which is equal to 2, where ̂ is the sample MAF) and relative risk for a disease with prevalence . This weighting approach adjusts for differences 1 between the empirical distribution of MACs across variants in real data, and the theoretical MAC 2 distribution for a variant with the specified MAF, effect size, prevalence in a GWAS with sample 3 size and case-control ratio . 4
The second weighting term PS accounts for the probability that a variant with the 5 specified population MAF is population-specific (monomorphic outside the target population), 6 and is defined 7
where ̂( ) is the fraction of variants that are population-specific among variants with MAF= 9 in the target population. This adjustment factor ensures that the weight assigned to population-10 specific variants in power calculations reflects the probability that a variant with the specified 11 population MAF is population-specific. 12 13 1 First, we compare strategies to improve imputation using study-specific WGS data for 2 African Americans, Latino Americans, Sardinians, and Finns. Next, we assess the effects of 3 genotyping array on imputation quality and coverage for each population and reference panel. We 4 then use these results to estimate statistical power to detect association as a function of study-5 specific panel size, number of participants imputed, external reference panel, and genotyping 6 array. Finally, we identify cost-effective study designs by comparing statistical power and total 7 experimental (sequencing and genotyping) costs for sequencing-only, imputation-only, and 8 sequencing-and-imputation GWAS designs for each population and genotyping array. 9
Strategies to Improve Imputation using Study-Specific WGS Data 10
We compared imputation 2 and coverage (proportion of variants with imputation 2 > 0.3 11 and reference MAC ≥ 5) for three imputation strategies: (1) using an external reference panel (the 12 HRC or HRC subset) alone, (2) using an augmented reference panel that combines the study-13 specific and external panels, and (3) using a study-specific reference panel alone. individuals from the study population improved overall imputation coverage for MAF=0.25-0.5% 6 variants by 4% for Finns, 9% for Latino Americans, 16% for African Americans, and 23% for 7
Sardinians genotyped using the OmniExpress relative to the external panel alone (Figure 1 ). 8
Similarly, augmenting the external reference panel with even 200 individuals increased imputation 9 coverage for MAF=0.1-0.25% variants by 3%, 4%, 6%, 10% relative to the external panel alone 10 for Finns, Latino Americans, African Americans, and Sardinians, respectively. 11
With 2,000 individuals from the target population (or 1,500 for Latino Americans), 12 population-specific panels provided roughly equivalent imputation 2 compared to augmented 13 panels (Supplemental Figure 1A) ; however, augmented panels provided higher imputation 14 coverage overall for low MAF variants (Supplemental Figure 1B) . For example, augmented panels 15 with 2,000 individuals from the target population (or 1,500 for Latino Americans) provided 86%, 16 80%, 79%, and 86% coverage for 0.1-0.25% MAF variants for Finns, Latino Americans, African 17 Americans, and Sardinians respectively, whereas population-specific panels alone provided 72%, 18 51%, 78%, and 72% coverage using the Omni Express array. However, imputation coverage for 19 variants with MAF>0.25% differed by <1% between augmented and population-specific panels 20 with 2,000 individuals from the target population (or 1,500 for Latino Americans) for all 21 populations and genotyping arrays. When a smaller number (less than 500) of individuals from the 22 target population are sequenced, augmented reference panels provided substantially higher 23 imputation coverage and 2 than population-specific panels alone. For example, augmented panels 1 with 500 individuals from the target population provided 90%, 85%, 65%, and 85% coverage for 2 0.25-0.5% MAF variants for Finns, Latino Americans, African Americans, and Sardinians 3 respectively, whereas population-specific panels of 500 individuals provided <30% coverage 4 using the Omni Express array. 5
Even very rare variants (MAF=0.1-0.25%) attained high coverage across all populations 6
given a sufficient number of population-matched individuals in the reference panel. For example, 7 attaining >70% imputation coverage for MAF=0.1-0.25% variants required a study-specific panel 8 of >1,800 individuals for African Americans, 1,000 for Latino Americans, 700 for Sardinians, and 9 0 for Finns using the OmniExpress. These increases in imputation coverage primarily reflect 10 increasing numbers of population-specific variants captured in the reference panel, which are 11 absent from or present in low copy number in the external panel. 12
Imputation Coverage and Quality across Genotyping Arrays 13
Imputation coverage was generally similar for the OmniExpress and Omni2.5 arrays, but 14 consistently lower for the less dense Core array. Coverage differed by <7% between the 15 OmniExpress and Omni2.5 across all MAF bins, populations, and reference panels, whereas the 16 Core provided up to 24% lower coverage than the Omni2.5 (Figure 1 , upper panels). Imputation 17 coverage was more heterogeneous across arrays for populations with greater genetic distance from 18 the external reference panel (e.g., African Americans and the HRC panel), particularly with smaller 19 (or absent) study-specific panels. Because we used the same reference panels for each genotyping 20 array, differences in imputation coverage between arrays are solely due to differences in the 21
proportion of variants that attained imputation 2 ≥ 0.3. Imputation 2 varied more across 22 genotyping arrays than did imputation coverage (Figure 1 , lower versus upper panels); however, 
Powerful and Cost-Effective Strategies for GWAS across Populations 3
We compared the cost-effectiveness of sequencing-only, imputation-only, and sequencing-4 and-imputation strategies by analyzing statistical power to detect association as a function of 5 numbers of study participants sequenced and imputed, genotyping array, and reference panel 6 across a range of genetic models. Here, we define the most cost-effective strategy as either (1) 7 minimizing total experimental (sequencing and genotyping) cost while attaining power at or above 8 a given threshold, or equivalently (2) maximizing power while maintaining cost no greater than a 9 specified constraint. 10
The cost-effectiveness of sequencing a subset of study participants varied greatly across 11 populations. For Finns, imputation-only designs were most powerful to detect association and 12 adding sequenced individuals increased power only minimally, even for low-frequency and rare 13 variants. For Sardinians, Latino Americans, and African Americans, sequencing a subset of study 14 participants was optimal, and often achieved substantially greater power than imputation-only or 15 sequencing-only studies. For example, a GWAS of African Americans with equal numbers of 16 cases and controls in which 400 participants are sequenced and 11,100 are imputed using the 17 Illumina Infinium Core array has 90% power to detect a risk variant with MAF = 0.5% and RR = 18 4 for a disease with prevalence 1%, whereas an imputation-only GWAS with the same total cost 19 (19,250 participants) has only 68% power (Figure 2 ). Even for populations in which optimal 20 sequencing-and-imputation designs had substantially greater power than imputation-only, the 21 optimal number to sequence was often modest. For example, only 210 participants are sequenced 22 under the optimal design using the Illumina OmniExpress to attain 80% power in the previousexample ( Figure 3 ). This is expected because even a relatively small study-specific panel can 1 substantially increase imputation coverage (Figure 1, upper panels) . 2
Denser Genotyping Arrays vs. Sequencing: Which is More Cost-Effective to Increase Power? 3
Imputation coverage and power to detect association can be increased by using denser 4 genotyping arrays, which provide a more informative framework for imputation, or by sequencing 5 population-matched individuals and augmenting the reference panel. We assessed the cost-6 effectiveness of these two strategies by comparing power to detect association across genotyping 7 arrays for study designs that have the same total cost assuming $1000 for WGS and current list 8 prices for genotyping arrays ( Table 1) . As expected, the optimal number of participants sequenced 9 to maximize power given fixed total cost generally decreased with increasing array density. For 10 example, the optimal number sequenced to maximize power to detect association was 500, 300, 11 and 90 for the Infinium Core, OmniExpress, and Omni2.5 respectively for Sardinians given total 12 sequencing and genotyping budget of $2M for a risk variant with RR = 2, MAF = 1%, and disease 13 prevalence 1%. Power to detect association under the optimal design given a fixed total cost was 14 generally greater for sparser arrays; in the previous example, power under the optimal design was 15 98%, 91%, and 55% for the Infinium Core, OmniExpress, Omni2.5. 16 We also compared optimal designs to attain power above a given threshold at minimum 17 total cost across genotyping arrays based on the per-sample array genotyping costs reported in 18 Table 1 . Generally, sparser arrays were more cost-effective (reached the power threshold with 19 lower total cost) than dense arrays. In fact, the sparsest genotyping array in our analysis, the 20 Infinium Core, was most cost-effective across all disease models and populations apart from 21
African Americans, for whom the Infinium OmniExpress was most cost-effective for some rare-22 variant disease models. This last result is unsurprising given the substantial difference in 
Power to detect association for case-control studies with equal numbers of cases and controls as a function of sequenced subsample 3 size (x-axis) and imputed subsample size (y-axis) for a variant with MAF 0.5% and relative risk 4 for a disease with prevalence 1%. 4
Axes are scaled to reflect costs of genotyping arrays ( (e.g., upper-left panel) . 8 9 sequencing/genotyping. Under these assumptions, we found that denser arrays are generally less 4 cost-effective than sparser arrays; of course, denser arrays provide higher imputation coverage 5
given a fixed GWAS sample size. 6
Optimal Study Design as a Function of Minor Allele Frequency and Effect Size 7
Power to detect association under a given study design depends on MAF, effect size 8 (relative risk or odds ratio), and population prevalence 29 . These parameters also influence the 9 relative cost-effectiveness of sequencing and imputation. While common variants can be 10 accurately imputed with small reference panels, large population-matched reference panels are 11 needed to capture rare (population-specific) variants. In Figure 3 , we illustrate the impact of 12 sequencing on statistical power for two combinations of MAF and effect size in each of the four 13 study populations. 14 The optimal percentage of study participants sequenced to attain ≥80% power to detect 15 association at minimum total cost increases with decreasing MAF (Figure 4) . This is expected, 16 since larger reference panels are needed to capture variants with lower frequency. Finally, the 17 optimal percentage of study participants sequenced to attain ≥80% power decreases with 18 increasing effect size magnitude. This is expected, since the expected number of risk alleles 19 captured in the reference panel increases with effect size magnitude. 20 While the cost of genome sequencing has fallen dramatically 29 , large genome sequencing 2 studies remain prohibitively expensive. Large imputation reference panels are now enabling 3 accurate imputation of even very rare variants (MAF>0.001) 9; 13; 30 , making imputation-based 4 GWAS viable and cost-effective for detecting associations across much of the allele frequency 5 spectrum. For populations with limited reference panel data, we have shown that sequencing a 6 subset of study participants can substantially increase imputation coverage and accuracy, 7 particularly for rare and population-specific variants, at a fraction of the cost of sequencing the 8 entire study cohort. Our results also suggest that it is almost always advantageous to augment 9 existing reference panels, except when the study-specific sequenced panel is large or the target 10 population has high genetic distance from the external panel. 11
Complementary sequencing-and-imputation GWAS strategies have been applied to refine 12 association signals and discover novel associations for several populations and complex traits 12; 19; 13 20 . While most sequencing-and-imputation studies to date have been carried out in European 14 isolated populations, our results suggest that this strategy can also be powerful and cost-effective 15 for admixed and non-European populations. In addition to increasing genomic coverage and power 16 to detect association for the study itself, sequencing a subset of study participants provides a data 17 resource that can be used to enhance imputation in future studies of the same or related populations 18 so long as the sequence data can be shared. 19
Directly augmenting an existing reference panel with study-specific sequence data is not 20 always feasible due to technical, logistical, and privacy constraints. However, we and others have 21
found that the distributed reference panel approach (separately imputing with two or more 22 reference panels and combining the results) provides nearly equivalent imputation quality 23 (Supplemental Figure 2) . Thus, study-specific WGS data can be used to improve imputation even 1 when directly augmenting an external panel is not feasible. 2
While large reference panels enable accurate imputation across a wide range of the allele 3 frequency spectrum 9; 13 , the extent of genetic variation that can be captured through imputation is 4 limited relative to WGS. For example, de novo mutations cannot be imputed regardless of 5 reference panel size. This is particularly salient for monogenic disorders; for example, over 80% 6 of achondroplasia cases occur from recurrent de novo mutations in FGFR3 31 . Thus, imputation 7 may be unable to detect causative alleles for traits with extreme genetic architectures, even with 8 very large reference panels. 9
As increasingly large and diverse sequencing projects are conducted, larger and more diverse 10 reference panels will become available. In the design and planning of GWAS, it may be prudent 11 to consider resources under development and pending release in addition to resources that are 12 currently available. More broadly, our analysis highlights the utility of collaboration and 13 coordination across institutions for effective study design and resource allocation. For example, 14 the optimal design to maximize power in an individual study does not necessarily maximize meta-15 analysis power across multiple studies of the same trait and population. 16 Our analysis of cost-effectiveness and optimal design depends crucially on the relative per-17 sample costs of sequencing and array genotyping. Both sequencing and array genotyping costs 18 have fallen markedly in recent years, and are likely to continue to do so. Depending on the relative 19 rates of change, cost-effectiveness and optimal design also may change. In addition, the cost of 20 participant recruitment and DNA sample collection may alter the relative cost-effectiveness of 21 sequencing and genotyping. Finally, our cost-effectiveness analysis assumes that sample size is 22 unconstrained; this may not apply for small populations or rare diseases. 23
While our results are illustrative, investigators may wish to explore questions of the relative 1 cost-effectiveness of sequencing and array genotyping strategies in the context of their own study 2 and relevant assumptions about population, reference panels, and sequencing and array genotyping 3 costs. To enable this exploration, we have developed a flexible, easy-to-use tool, APSIS (Analysis 4 of Power for Sequencing and Imputation Studies), which is open source and freely available (see 5
Web Resources). 6
Conclusions 7
Here, we assessed the genomic coverage, statistical power, and cost-effectiveness of 8 sequencing and imputation-based designs for GWAS in four populations across a range of genetic 9 models. We developed a novel method to account for available reference haplotype data in power 10 calculations using empirical data, which can be applied to inform GWAS planning and design. For 11
European populations that are well-represented in current reference panels, our results suggest that 12 imputation-based GWAS is cost-effective and well-powered to detect both common-and rare-13 variant associations. For populations with limited representation in current reference panels, we 14 found that sequencing a subset of study participants can substantially increase genomic coverage 15 and power to detect association, particularly for rare and population-specific variants. Our results 16 also suggest that larger and more diverse reference panels will be important to facilitate array-17 based GWAS in global populations. 18 
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